Track protection status across key markets to assess launch feasibility.
It is formulated by 31 pharmaceutical companies such as ACTAVIS MID ATLANTIC, PADAGIS US, TARO and others. It is marketed under 5 brand names, including CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE (EMOLLIENT), IMPOYZ and others. Available in 2 different strengths, such as 0.05%, 0.025%, and administered through 9 routes including SHAMPOO;TOPICAL, SPRAY;TOPICAL, LOTION;TOPICAL and others.
API availability: Loading API feasibility...
Licensing: 31 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
Strength | Route of Administration | Companies | Latest Approval Date |
---|
Patents approved by the FDA for the ingredient
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
---|---|---|---|---|---|
{"application_id":"43106","ingredient":"CLOBETASOL PROPIONATE","trade_name":"OLUX E","family_id":"4c18997e3c5142658a32","publication_number":"US8962000B2","cleaned_patent_number":"8962000","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-08-31","publication_date":"2015-02-24","legal_status":"Granted"} | US8962000B2 Formulation | 24 Feb, 2015 | Granted | 31 Aug, 2025 | |
{"application_id":"43088","ingredient":"CLOBETASOL PROPIONATE","trade_name":"OLUX E","family_id":"4c18997e3c5142658a32","publication_number":"US8460641B2","cleaned_patent_number":"8460641","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-11-05","publication_date":"2013-06-11","legal_status":"Granted"} | US8460641B2 Formulation | 11 Jun, 2013 | Granted | 05 Nov, 2028 | |
{"application_id":"54720","ingredient":"CLOBETASOL PROPIONATE","trade_name":"IMPOYZ","family_id":"14b6959345fc44e3b23e","publication_number":"US9956231B1","cleaned_patent_number":"9956231","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-08-31","publication_date":"2018-05-01","legal_status":"Granted"} | US9956231B2 Formulation | 01 May, 2018 | Granted | 31 Aug, 2030 | |
{"application_id":"54722","ingredient":"CLOBETASOL PROPIONATE","trade_name":"IMPOYZ","family_id":"14b6959345fc44e3b23e","publication_number":"US10588914B2","cleaned_patent_number":"10588914","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-08-31","publication_date":"2020-03-17","legal_status":"Granted"} | US10588914B2 Formulation | 17 Mar, 2020 | Granted | 31 Aug, 2030 | |
{"application_id":"54708","ingredient":"CLOBETASOL PROPIONATE","trade_name":"IMPOYZ","family_id":"14b6959345fc44e3b23e","publication_number":"US10064875B2","cleaned_patent_number":"10064875","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-08-31","publication_date":"2018-09-04","legal_status":"Granted"} | US10064875B2 Formulation | 04 Sep, 2018 | Granted | 31 Aug, 2030 | |
{"application_id":"54729","ingredient":"CLOBETASOL PROPIONATE","trade_name":"IMPOYZ","family_id":"0be2fba8ffb448e3a67f","publication_number":"US9855334B2","cleaned_patent_number":"9855334","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-03-11","publication_date":"2018-01-02","legal_status":"Granted"} | US9855334B2 Formulation | 02 Jan, 2018 | Granted | 11 Mar, 2035 | |
{"application_id":"122910","ingredient":"CLOBETASOL PROPIONATE","trade_name":"BYQLOVI","family_id":"","publication_number":"US10588913B2","cleaned_patent_number":"10588913","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-05-09","publication_date":"2020-03-17","legal_status":"Granted"} | US10588913B2 Formulation | 17 Mar, 2020 | Granted | 09 May, 2036 | |
{"application_id":"122909","ingredient":"CLOBETASOL PROPIONATE","trade_name":"BYQLOVI","family_id":"","publication_number":"US11376262B2","cleaned_patent_number":"11376262","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-05-09","publication_date":"2022-07-05","legal_status":"Granted"} | US11376262B2 Formulation | 05 Jul, 2022 | Granted | 09 May, 2036 |
Latest clinical trials and research studies for this ingredient
NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
---|
Manufacturing Locations
Unlock access to all suppliers of Clobetasol Propionate
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.